News: Affymetrix, Inc. (AFFX.O)

AFFX.O on Nasdaq

5.67USD
4:00pm EST
Price Change (% chg)

$-0.23 (-3.90%)
Prev Close
$5.90
Open
$5.70
Day's High
$5.90
Day's Low
$5.59
Volume
1,403,340
Avg. Vol
1,405,235
52-wk High
$10.06
52-wk Low
$1.78

view news for:
Select another date:

Wed, Nov 4 2009

HEADLINE STOCKS-U.S. small/midcap stocks on the move on Nov 4

The company said FDA granted orphan drug status to its experimental pancreatic cancer treatment. [ID:nWNAB9831]

Continue Reading

HEADLINE STOCKS-U.S. small/midcap stocks on the move on Nov 4

Nov 4 (Reuters) - Some small and midcap stocks on the move on Wednesday:

US SMALL/MIDCAPS-Earnings lift F5, J Crew; Affymetrix slips

NEW YORK, Oct 22 (Reuters) - Stocks posting solid earnings and positive outlooks such as J Crew and F5 Networks were rewarded by investors on Thursday, while those that fell short of expectations, including Affymetrix, took heavy losses.

UPDATE 1-Affymetrix shares fall after Q4 rev view misses market

(Adds details, analysts' comments, updates share movement)

HEADLINE STOCKS-Some U.S. stocks to watch on July 23

NEW YORK, July 23 (Reuters) - Some U.S. stocks to watch on Thursday:

UPDATE 1-Affymetrix posts Q2 profit, shares rise

July 22 (Reuters) - Affymetrix Inc , which makes arrays to analyze genetic data, posted a quarterly profit helped by a gain on debt repurchase, sending its shares up 8 percent.

UPDATE 1-Agilent wins patent fight with Affymetrix

WASHINGTON, June 4 (Reuters) - A U.S. patent appeals court ruled on Thursday in favor of Agilent Technologies , which had been involved in a patent fight with Affymetrix Inc .

UPDATE 1-Illumina Q4 results beats Street, strong Q1, 2009 view

Feb 3 (Reuters) - Illumina Inc , which makes tools for genetic analysis, posted better-than-expected quarterly results and forecast first-quarter outlook above analysts' estimates, even as other tool makers struggle with falling sales.

UPDATE 2-Affymetrix posts wider-than-expected Q4 loss

* Total revenue falls 27 pct (Adds details from conference call)

UPDATE 1-RESEARCH ALERT-Baird cuts Beckman Coulter to neutral

Dec 15 (Reuters) - Robert W. Baird downgraded Beckman Coulter to "neutral" from "outperform," and cut its price targets on several life-sciences and diagnostic device makers, saying it was concerned about the global environment impacting capital expenditure decisions in the short-term.

Select another date:

Market Views

» More AFFX.O Market Views

Press Releases

view news for: